目的： 临床研究加速康复外科（ERAS）在肝癌肝移植中应用的安全、有效性。方法： 回顾性对比分析我院自2016年6月至2018年12月实施围术期ERAS管理的24例肝癌肝移植病人和28例（2014年1月至2016年5月）对照组的临床资料,研究ERAS在肝癌肝移植中应用的安全、有效性。结果： ERAS组的术中输液总量明显少于对照组（P<0.05）。术后气管插管、动脉导管、深静脉导管、胃管、导尿管、引流管的拔管时间以及恢复正常饮食时间早于对照组（P<0.05）。肝功能恢复、ICU治疗及住院时间均短于对照组（P<0.05）。两组术前基线资料、供体冷缺血时间、手术时间、无肝期、无输血病人百分比、出血量、输血量的差异均无统计学意义（P>0.05）。两组术后再插管例数、主要并发症发生率、死亡率及出院后1个月内再入院率的差异均无统计学意义（P>0.05）。结论： 在部分肝癌肝移植病人中实施ERAS安全、有效,可缩短ICU治疗时间和住院时间。

Objective To investigate the effect and safety of enhanced recovery after surgery(ERAS) in liver transplantation for hepatocellular carcinoma. Methods A retrospective study was performed to compare the clinical results of periopertive ERAS of 24 patients with liver transplatation for hepatcelllualr carcinoma in ERAS group from June 2016 to December 2018 with those of 28 patients in control group without ERAS protocol from January 2014 to May 2016. Results There was less fluid volume intraoperatively in ERAS group compared to that in control group(P<0.05). Earlier remove drain and tube including intubation and nasogastric tube, arterial and deep venous catheters, urinary catheter and abdominal drain combined with earlier normal food intake were gotten in ERAS group compared with those in control group(P<0.05). There were earlier return to normal hepatic function and less stay in both ICU and hospital in ERAS group than in control group(P<0.05). However, no differences between two groups were observed in preoperative data, duration of donor cold ischemia, operative time, ahepatic phrase, no transfusion ratio, amount of blood loss and blood transfused, postoperative complications and mortality and 1-month readmission rates (P>0.05). Conclusions ERAS is feasible and safe in some patients with hepatocellular carcinoma during liver transplantation with less stay in both ICU and hospital.